Key Drivers
- High margins
- Weak liquidity
- Low ROIC
AIAI Summary
CooperCompanies should be re‑rated as a cash‑flow and margin story rather than a pure revenue growth name—investors should demand clear, repeatable evidence of sustained MyDay/MiSight-driven margin expansion and FCF conversion (stabilized working capital and normalized capex) before increasing exposure, since low cash, meaningful debt and APAC execution risk could quickly reverse gains.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Weak liquidity
- •Low ROIC
CooperCompanies shows strong operating profitability and positive FCF but declining liquidity, modest ROIC/ROE and large intangibles that compress tangible equity versus the market price.
Price Behavior
Key Price Behavior Insights:
- •Downtrend dominant
- •Deeply oversold
- •Support tested
COO has entered a decisive downtrend over the last month—price has broken a nearby support and trades well below the last-month SMA while RSI is deeply oversold, leaving room for a short-term bounce but raising risk of further trend-following selling.
Broke down through nearby support and sits well below the last-month (21-day)
Sentiment & News
Key News Insights:
- •EPS beat
- •Guidance raised
- •Technical weakness
CooperCompanies beat Q1 EPS and raised FY26 guidance on product-driven growth and margin expansion, but the stock slid amid mix/tariff headwinds and short-term technical selling despite analyst upward revisions.
Raised guidance and solid product momentum support the longer-term bull case, but near-term international/mix risks and recent selling pressure could limit immediate upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings